CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Using a novel “unlocking” coronary device may reduce the risk of target lesion failure between 6 months and 2 years by nearly 50%, based on an analysis from the INFINITY-SWEDEHEART trial presented at this year's #TCT2025. www.tctmd.com/news/infinit...

Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Performing PCI to open up the graft for patients with failed SVGs after CABG reduces the rate of major CV events compared with intervening on the bypassed native coronary artery, according to results from the PROCTOR trial. #TCT2025 www.tctmd.com/news/proctor...

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

Three-year data from the LIFE-BTK trial shows that a drug-eluting resorbable scaffold continues to keep many patients with below-the-knee chronic limb-threatening ischemia free from repeat procedures even after it dissolves. #TCT2025 www.tctmd.com/news/life-bt...

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

TMVR with the Tendyne system successfully treats MR or stenosis complicated by severe MAC, improving heart failure symptoms and quality of life, according to findings from the SUMMIT-MAC study presented at #TCT2025. More here: www.tctmd.com/news/tendyne...

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

In the US, 10 million older people, two-thirds of them women, have mild or greater valvular heart disease, based on data from the PREVUE-VALVE study. To optimize screening, "we need to understand the true prevalence of VHD–how much there is," said David Cohen. #TCT2025 www.tctmd.com/news/prevue-...

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

On this episode of Heart Valve Matters, Patrick O’Gara and Sean Pinney discuss the evaluation and treatment of patients with severe tricuspid regurgitation. Listen now: www.tctmd.com/audio/tricus...

Longer-term results from the PARTNER 3 trial presented at #TCT2025 showed that both surgery and TAVI continued to have stable outcomes and no signs of valve failure in low-risk patients with symptomatic severe aortic stenosis at 7 years. www.tctmd.com/news/partner...

Heavy Alcohol Use Tied to More-Severe Intracerebral Hemorrhages

Tricuspid Series: Heart Failure Management

During #TCT2025 in San Francisco, @mmamas1973.bsky.social and Evald Christiansen discuss the late-breaking NOBLE trial. Watch the full episode of Beyond the Data: www.tctmd.com/videos/beyon...

On this episode of Rox Heart Radio, Roxana Mehran and Brahmajee Nallamothu give a preview of what to expect at AHA 2025 in New Orleans. Listen now: www.tctmd.com/audio/rox-he...

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains

The cardiovascular benefits of semaglutide are only partially tied to weight loss, according to analysis from the SELECT trial. More research is especially needed to see if GLP-1 RAs lower the risk of MACE. www.tctmd.com/news/semaglu...

What’s Going to Be Hot at AHA 2025?

Rox Heart Radio: AHA 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

What Makes MedTech Great—or Not—and Envisioning Its Future

Both men and women who alter their alcohol consumption, even at moderate levels, can positively affect their BP, based on a Japanese study. "Even light-to-moderate drinkers can gain measurable benefit from stopping alcohol," said lead author Takahiro Suzuki. www.tctmd.com/news/alterat...

At #TCT2025 in San Francisco, @mmamas1973.bsky.social and Josep Rodés-Cabau discuss short-term anticoagulation vs DAPT post-LAAO in this episode of Beyond the Data. Watch it now: www.tctmd.com/videos/beyon...

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES www.tctmd.com/news/doac-ma...

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCTMD’s Top 10 Most Popular Stories for October 2025

Listen to the latest episode of the Talking Points podcast where @mmamas1973.bsky.social and Gi-byoung Nam discuss the EPIC-CAD trial. www.tctmd.com/audio/epic-c...

Older women who took at least 4,000 steps a day had significantly reduced risks of all-cause mortality and cardiovascular disease, according to a new study. Read more here: www.tctmd.com/news/little-...

Supporters of transcatheter tricuspid valve interventions for severe TR are reassured by new real-world and extended trial data, presented at this year's #TCT2025. But longer-term follow up is still needed to answer continued questions on safety and efficacy. www.tctmd.com/news/more-da...

The use of cutting and noncompliant balloons for lesion preparation may provide results similar to Shockwave intravascular lithotripsy in patients with significant coronary lesion calcification who require PCI. #TCT2025 www.tctmd.com/news/trials-...

Suzanne Baron and Matthias Bossard sit down with Mamas Mamas (@mmamas1973.bsky.social) to discuss the Short-Cut and VICTORY trials presented earlier this week at #TCT2025. Watch the full video: tctmd.com/videos/beyon...

Patients with acute intermediate-high-risk PE who undergo mechanical thrombectomy have a greater reduction in the RV/LV ratio at 48 hours than those treated with anticoagulation alone, according to results from the first-of-its-kind STORM-PE RCT. #TCT2025 www.tctmd.com/news/mechani...

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations

The need for a cardiac implantable electronic device (CIED) before or after undergoing TTVR does not have a significant impact on all-cause death or hospitalization for HF at 1 year, according to an analysis of TRISCEND and TRISCEND II. #TCT2025 www.tctmd.com/news/ttvr-re...

Cardiologists Saw Rising Incomes but Additional Pressures in 2024: MedAxiom

CMS Greenlights Reimbursement for Renal Denervation Systems

The EPIC-CAD Trial

A heartfelt thank you ✨ to all who helped make #TCT2025 the premier global forum for #interventionalcardiology! 🫀 But the innovation and education don’t stop here. Mark your calendars for #TCT2026! 📆🚀 #CardioSky #MedSky